VIDEO: TearCare shows superiority to Restasis for meibomian gland secretion score in DED
Click Here to Manage Email Alerts
SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Preeya K. Gupta, MD, discusses a clinical trial comparing the TearCare system with Restasis for the treatment of dry eye disease and meibomian gland dysfunction.
According to Gupta, patients in the SAHARA trial who were treated with TearCare were dosed once at baseline and again at 5 months, while patients treated with Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan) received one drop twice a day throughout treatment.
“TearCare was found to be superior and offered a greater improvement across all time points in tear break up time, conjunctival staining and meibomian gland secretion score, and this was similar in both males and females,” she said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts